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Abstract
Background: Accurate tests to diagnose adenocarcinoma and high-grade dysplasia among mucinous pancreatic
cysts are clinically needed. This study evaluated the diagnostic utility of amphiregulin (AREG) as a pancreatic cyst
fluid biomarker to differentiate non-mucinous, benign mucinous, and malignant mucinous cysts.
Methods: A single-center retrospective study to evaluate AREG levels in pancreatic cyst fluid by ELISA from 33
patients with a histological gold standard was performed.
Results: Among the cyst fluid samples, the median (IQR) AREG levels for non-mucinous (n = 6), benign mucinous
(n = 15), and cancerous cysts (n = 15) were 85 pg/ml (47-168), 63 pg/ml (30-847), and 986 pg/ml (417-3160),
respectively. A significant difference between benign mucinous and malignant mucinous cysts was observed (p =
0.025). AREG levels greater than 300 pg/ml possessed a diagnostic accuracy for cancer or high-grade dysplasia of
78% (sensitivity 83%, specificity 73%).
Conclusion: Cyst fluid AREG levels are significantly higher in cancerous and high-grade dysplastic cysts compared
to benign mucinous cysts. Thus AREG exhibits potential clinical utility in the evaluation of pancreatic cysts.
Background
Pancreatic cysts are increasingly recognized from rou-
tine use of computed tomography and magnetic reso-
nance imaging with current prevalence estimates of 2%
in the population, rising to approximately 8% in the
elderly [1,2]. Appropriate diagnosis and management of
these cysts is clinically important because approximately
half may have potential for malignant transformation to
pancreatic adenocarcinoma - a cancer associated with
an overall 5-year survival rate of 5% [3,4]. Cysts with
malignant potential include mucinous cystic neoplasms
(MCN) and intraductal papillary mucinous neoplasms
(IPMN).
Various diagnostic tests, including endoscopic ultra-
sound (EUS), are employed to facilitate diagnosis and
management of pancreatic cysts [5,6]. EUS guided
aspiration of cyst fluid provides an opportunity to evalu-
ate for tumor markers such as carcinoembryonic antigen
(CEA) that can differentiate mucinous from non-muci-
nous cysts with reasonable accuracy. CEA cannot, how-
ever, accurately differentiate pre-malignant cysts from
malignant cysts [7]. Further, cyst fluid cytology also pos-
sesses low sensitivity for diagnosing malignancy [8].
Because progression to cancer may be slow and variable
among pre-malignant mucinous cysts, a biomarker that
identifies cysts with cancer or high-grade dysplasia may
have clinical value by identifying which patients may
benefit from immediate consideration for surgery [9-12].
In this study, the diagnostic utility of the secreted epi-
dermal growth factor receptor ligand, amphiregulin
(AREG), was explored as a cyst fluid biomarker for the
presence of malignancy in pancreatic cysts. AREG was
chosen based on previous gene expression studies that
identified enhanced Anterior Gradient 2 (AGR2) expres-
sion in all pancreatic adenocarcinomas [13]. AGR2 sti-
mulates adenocarcinoma cell growth and supports the
development of many features associated with malignant
transformation [14,15]. A recent study demonstrated
that AGR2’s growth promoting properties are achieved
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noma cells [16]. As a secreted molecule, we hypothe-
sized that the AREG concentration within the cyst fluid
of adenocarcinomas or high-grade dysplastic lesions
possesses diagnostic utility in the evaluation of pancrea-
tic cysts.
Methods
Cyst fluid samples
With the approval of the Stanford University Human
Subjects Institutional Review Board, a pancreatic cyst
fluid bio-repository has been maintained since July 2008.
Patients evaluated at Stanford Hospital and Clinics for
endoscopic ultrasound or surgery for pancreatic cysts
were offered participation in the study. Cyst fluid was
collected at the time of endoscopic ultrasound and/or
surgery. Patients with a cyst large enough (typically
greater than 1 cm) to provide cyst fluid beyond what
was required for clinical evaluation was immediately
placed on ice, aliquoted, and stored at -80°C. Clinical
evaluation of the cyst fluid primarily involved 500
microliters of fluid for CEA analysis. Testing for amylase
was left to the clinical discretion of the gastroenterolo-
gist or surgeon. When an intracystic nodule was seen,
the nodule underwent fine needle aspiration for tissue
diagnosis. All samples were aliquoted and frozen at
-80°C within 30 minutes of collection. All samples
assayed were subjected to no more than two freeze-thaw
cycles, which does not affect the assay’s reproducibility.
Diagnosis of pancreatic cysts
Cyst diagnosis was determined by surgical pathology or
cytology. In each of the surgically resected cases, histol-
ogy slides were independently evaluated by a pathologist
(RKP) for the histology type and grade of the neoplasm.
All cases of IPMN and MCN were subclassified based
on the grade of dysplasia: low-grade, intermediate-grade,
and high-grade, using the WHO classification [17]. In
this study, the definition of cancer included cystic
lesions with high-grade dysplasia. Benign mucinous
cysts included MCN or IPMN lesions with low- or
intermediate-grade dysplasia.
AREG ELISA
Researchers (M.T.T., A.W.L.) blinded to the patients’
diagnoses conducted the AREG ELISAs. Cyst fluid
AREG was determined using a two-antibody sandwich
ELISA (DY262, R&D systems, Minneapolis, MN)
according to the manufacturer’s instructions. Standard
curves were reproducible over a dynamic range of 5-
2,000 pg/ml. Briefly, 100 microliter (ul) of sample was
required for analysis and added to a 96-well ELISA plate
(Fisher Scientific, Pittsburg, PA) that had been pre-
coated with the capture antibody. After incubation with
the detection antibody and streptavidin-HRP, the signal
was developed by the addition of 3,3’,5,5’-tetramethyl-
benzidine (TMB, Thermo Scientific, Rockford, IL), fol-
lowed by the addition of a stop solution, and quantified
by absorptive spectrophotometry at 450 and 562 nm on
an automatic plate reader (Biotek, Winooski, VT).
Assays for each sample were performed on serially
diluted aliquots and performed in duplicate. The diluent
consisted of 1% bovine serum albumin in phosphate
buffered saline, pH 7.3. Dilutions within the assay’sl i n -
ear range on the standard curve were chosen. Data
demonstrating that the ELISA specifically measures the
AREG gene product was previously established [16].
Statistical analysis
Comparisons between mucinous and non-mucinous
cysts and benign mucinous and malignant mucinous
cysts were performed. Based on a non-normal distribu-
tion of AREG levels by cyst type, the non-parametric
Kruskal-Wallis test was used to compare AREG levels
between the multiple categories of cysts. The Wilcoxon
rank-sum test was used for comparison of 2 cyst types.
A receiver operator curve was generated to characterize
the accuracy of cyst fluid AREG to diagnose malignant
mucinous cysts. When a significant difference was
observed, a threshold with highest diagnostic accuracy
was used to report the sensitivity and specificity of
AREG. Statistical analysis was performed using STATA
11.0 (College Station, TX).
Results
Patients and cyst types
Thirty-three patients with pancreatic cysts were evalu-
ated (Table 1). The mean age was 61 (range 33 - 83)
Table 1 Summary of Patient and Cyst Characteristics
Total Patients 33
Median Age, years (range) 61 (33- 83)
Gender: Male/Female 18 (54%)/15 (46%)
Median Cyst Size, cm (IQR) 2.8 (2.0 - 4.4)
Non-Mucinous 6
SCN (n = 4)
Pseudocyst (n = 1)
Other (n = 1)
Benign Mucinous 15
IPMN BD (n = 9)
IPMN MD (n = 3)
MCN (n = 3)
Cancer (in situ) 12
High Grade (n = 4)
Invasive (n = 8)
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was 2.8 cm (interquartile range [IQR] 2.0 - 4.4 cm). A
histological diagnosis was conferred by surgical pathol-
ogy for 30 samples and by cyst aspiration cytology for 3
samples. Among the 30 surgical pathology samples, there
were 5 adenocarcinomas, 4 cysts with high-grade dyspla-
sia (all MD-IPMN), 15 benign mucinous cysts (MCN = 3,
BD-IPMN = 9, and MD-IPMN = 3), and 6 non-mucinous
cysts (SCN = 4, PC = 1, squamous cyst = 1). Histological
samples conferred only by cytology (n = 3) were cysts
associated with unresectable adenocarcinoma.
Diagnostic accuracy of AREG
Scatter plots of cyst AREG levels by cyst type are shown
in Figure 1. The median (interquartile range, IQR) cyst
AREG levels for non-mucinous cysts, benign mucinous
cysts, and cancerous cysts were 85 pg/ml (47-168),
63 pg/ml (30-847), and 986 pg/ml (417-3160), respec-
tively. Table 2 summarizes cyst AREG values by each
type of cyst. No significant difference in AREG levels
was appreciated between non-mucinous and mucinous
cysts. When mucinous cysts were divided between
benign and cancerous cysts a significant difference in
cyst AREG levels was observed (p = 0.025).
Based on the difference of cyst AREG levels between
benign mucinous and mucinous cancers, a receiver opera-
tor curve (ROC) was generated to determine an optimal
threshold to diagnose mucinous cancers (Figure 2). As a
summary measure of diagnostic accuracy, the area under
the ROC was 0.76 (95% CI 0.56-0.95). At an AREG thresh-
old of greater than 300 pg/ml, the diagnostic accuracy for
cancer was 78% with a sensitivity of 83% and specificity of
73%. With the prevalence of cancer of 32% in the sample,
the positive and negative predictive value was 71% and
85%, respectively.
Further clinical details on the 12 patients with cancer
in this sample are highlighted in Table 3. Four patients
had high-grade dysplastic lesions, and included 3 MD-
IPMN. The majority of patients (10 out of 12) had
symptoms (i.e. jaundice, weight loss, abdominal pain)
associated with cancer. The majority of patients had
imaging evidence of a nodule within the cyst or an asso-
ciated mass (8 out of 12). Two out of the 12 cases had
AREG levels below 300 pg/ml. One case (AREG =1 2 5 )
was an intraductal oncocytic papillary neoplasm and the
other case (AREG = 4) was a 1.5 cm cyst adjacent to a
pancreatic adenocarcinoma.
Discussion
A biomarker that can accurately and reliably distinguish
cancer or high-grade dysplasia among mucinous pan-
creatic cystic neoplasms remains an important clinical
need. The most accepted cyst fluid biomarker currently
is CEA, which is good at differentiating mucinous from
Figure 1 Scatter plot of cyst AREG by non-mucinous, benign
mucinous, and malignant mucinous cysts.
Table 2 Summary of Cyst Fluid AREG performance by
Cyst Types
Cyst Type (n = 33) Median AREG (pg/ml) IQR (pg/ml)
Non-Mucinous (n = 6) 85 47-168
SCN (n = 4) 48 44-109
Pseudocyst (n = 1) 227
Other (n = 1) 121
Benign Mucinous (n = 15) 63 30-847
IPMN BD (n = 9) 48 29-63
IPMN MD (n = 3) 847 71-9041
MCN (n = 3) 202 42-1030
Cancer (in situ) 986 417-3160
High Grade (n = 4) 417 214-546
Invasive (n = 8) 2047 986-4367
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Figure 2 ROC curve analysis of AREG to differentiate benign
mucinous from malignant mucinous cysts.
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Page 3 of 6non-mucinous cysts. CEA, however, is not reliable for
differentiating cancer or high-grade dysplasia among
pre-malignant mucinous cysts. As a result, current prac-
tice relies on clinical and radiographic data to help clini-
cians decide which cystic lesions warrant immediate
surgery over observation [18]. While helpful, cases of
unnecessary surgery or missed opportunities to resect
cancer occur [19-21].
AREG’s discovery as a potential cyst fluid biomarker
arose from observations of increased Anterior Gradient
2( AGR2) gene expression among pancreatic adenocarci-
nomas [13]. AGR2 is a highly conserved gene that is
associated with mucus secreting cells. AGR2 stimulates
adenocarcinoma cell growth and supports the develop-
ment of many features associated with malignant trans-
formation [14,15]. Closer examination of the gene
expression studies showed that AGR2 expression was
significantly higher in MCN cysts compared to SCA
lesions. Recent studies revealed that AREG, a secreted
epidermal growth factor receptor ligand, is specifically
induced by AGR2 [16].
In this study, we examined the diagnostic utility of
AREG in pancreatic cyst fluid and observed no differ-
ence in cyst AREG concentrations between non-muci-
nous and benign mucinous cysts. Malignant mucinous
cysts that included high-grade dysplastic lesions, how-
ever, expressed a significantly higher AREG level (med-
ian 986 pg/ml) compared to benign mucinous cysts
(median 63 pg/ml) and non-mucinous cysts (median
85 pg/ml). By receiver operator curve analysis, an AREG
level of 300 pg/ml provided a diagnostic accuracy for
cancer of 78% (sensitivity 83%, specificity 73%). The
higher cyst AREG levels observed in malignant cysts is
likely a function of the total cellular mass of AREG pro-
ducing cells. As a benign cyst transitions to a malignant
cyst, a hallmark of dysplasia includes a change from
simple to stratified epithelium. We hypothesized that
this results in a significant increase in the cellular mass
of a cyst leading to increased cyst AREG expression.
The similarities in cyst AREG levels between non-muci-
nous and benign mucinous cysts may be related to the
physiologic expression of AREG as part of a reparative
process in combination with a smaller cellular mass of
mucin producing cells. Recent studies have determined
that AREG serves an important role in tissue repair
after damage in the gastrointestinal tract [22,23].
Because cyst CEA is fairly accurate in differentiating
non-mucinous from mucinous cysts, the diagnostic utility
of combining both CEA and AREG was considered. There
were 21 of the 33 samples where cyst fluid CEA and
AREG levels were available for analysis. The median (IQR)
CEA levels for the 4 non-mucinous cysts, 11 benign muci-
nous, and 6 malignant mucinous cysts were 127 ng/ml
(36-844), 1294 ng/ml (171-8600), and 2400 ng/ml (1245-
11962), respectively. Mucinous cysts (n = 17) had an
elevated CEA (median (IQR) 1311 ng/ml (277-8600))
compared to non-mucinous cysts (n = 4) (126 ng/ml (36-
844) (p = 0.09). Although this difference was not statisti-
cally significant, this is likely due to the small sample size.
Using a cutoff of 192 ng/ml, the sensitivity and specificity
of CEA to differentiate non-mucinous from mucinous
cysts was 76% and 75%, respectively- an observation simi-
lar to previous reports [7,24]. The small size of this sample
may also explain why no difference in sensitivity and spe-
cificity for cancer was observed when combining AREG
and CEA compared to AREG alone. When an AREG
Table 3 Summary Table of 12 patients with histological diagnosis of Cancer (includes high grade dysplasia)
Patient Age/
Gender
Symptomatic Cyst Size
(cm)
Location Mural Nodule/
Mass
AREG level
(pg/ml)
CEA level
(ng/ml)
Diagnosis
39/F Yes 2.8 Tail Yes 125 15 Intraductal Oncocytic Papillary
Neoplasm
72/M No 4.6 Body No 303 2298 Main Duct IPMN with High-Grade
Dysplasia
78/M Yes N/A Diffuse No 523 N/A Main Duct IPMN with High-Grade
Dysplasia
65/M Yes N/A Diffuse No 560 N/A Main Duct IPMN with High-Grade
Dysplasia
60/M No 1.5 Body Yes 4 1245 Adenocarcinoma
83/M Yes 3.0 Body Yes 694 42979 Adenocarcinoma
60/M Yes 3.0 Tail Yes 1279 N/A Adenocarcinoma
60/F Yes 3.2 Tail Yes 1567 11962 Adenocarcinoma
66/F Yes 2.6 Head Yes 2527 N/A Adenocarcinoma
70/M Yes N/A Diffuse No 3794 N/A Colloid Carcinoma
51/M Yes 3.0 Head Yes 4940 N/A Adenocarcinoma
65/M Yes 7.5 Head Yes 6458 2501 Adenocarcinoma
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malignant mucinous cysts, the sensitivity was 67% and the
specificity 80%. When AREG was sequentially tested only
on pancreatic cysts with a CEA level greater than 192 ng/
ml, neither the sensitivity nor specificity changed for
cancer.
There are several features of this study that limit the
generalizability of these observed results. First, this is a ret-
rospective single tertiary center with a relatively small
sample of cyst fluid samples. The small sample size is due
in part to restricting the study to surgical patients.
Although recruitment was difficult because patients with
pancreatic cysts often do not undergo surgery, it was felt
that as an initial proof-of-concept study, the use of pathol-
ogy and surgically resected samples was a necessary gold
standard to establish the correct diagnosis. As a result, the
impact of a small sample size (in particular the limited
cases of non-mucinous cysts) may include inadequate
power to demonstrate a difference between non-mucinous
and mucinous AREG levels should one truly exist. Second,
the 12 cancer cases (including high grade dysplasia) were
relatively advanced cases and could likely be identified by
current practices without cyst AREG. It is unclear how
AREG will perform in cases when imaging and clinical
characteristics are non-specific. Many of these limitations,
however, can be addressed in the future with prospective,
longitudinal validation incorporating a larger sample size
and multi-center collaboration.
Conclusions
The present study represents the translation of recent dis-
coveries in the basic biology of adenocarcinomas to clinical
utility in the evaluation of pancreatic cysts. The study
reports the discovery of AREG, a secreted epidermal
growth factor receptor ligand, as a biomarker with poten-
tial diagnostic utility for diagnosing and managing pancrea-
tic cystic neoplasms. Specifically, cyst AREG levels may
help accurately identify those cysts with cancer and high-
grade dysplastic lesions that require immediate surgical
attention. Although not a serum-based test, EUS mediated
acquisition of the 100 microliters of fluid necessary for ana-
lysis is within current practices for managing pancreatic
cysts, and will facilitate validation in future studies.
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